Medefil

United States Updated 9 July 2026

Medefil is a finished-dose manufacturer based in United States. It appears in 13 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 21 April 2025 as VAI.

active US DMFs

valid CEPs

registered plants 1 with an FDA FEI number

filings across 1 regulators

These figures were checked against the regulators' own files on 25 July 2026

Plants

1 of 1 confirmed

Inspections

8 of 8 confirmed

Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

21 April 2025 VAI US FDA
29 March 2018 VAI US FDA
17 June 2016 VAI US FDA
15 September 2014 VAI US FDA
20 December 2012 VAI US FDA
22 August 2012 NAI US FDA
25 May 2012 VAI US FDA
6 September 2011 OAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site	FDA FEI
Glendale Heights, United States	3001677091

Filings and GMP by regulator

Regulator	Filings	GMP certificates
US FDA	13	1

Comparing suppliers?

Choose your molecules and target markets. Medefil comes back tiered against every other supplier able to file there.

Start for free

No sales call.

Open risk flags

The most recent inspection outcome was VAI, on 21 April 2025.

Sources on this page

FDA: Drug master files, establishment registration, inspection classifications
EDQM: Certificates of suitability
EudraGMDP and national regulators: GMP certificates